MedTrace Logo

Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.

NCT00600171 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2016-12-16

Study results available
· View outcomes & findings →

Summary

This study is designed to determine if the investigational drug is effective and safe in individuals with asthma

Conditions

Interventions

DRUG

GW642444M

GW642444M

DRUG

Placebo

Placebo mulit-dose dry powder inhaler

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States
  • Argentina
  • Belgium
  • Canada
  • Chile
  • France
  • Germany
  • Netherlands
  • Peru
  • Philippines
  • Poland
  • Russia
  • South Africa
  • South Korea
  • Sweden
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00600171 on ClinicalTrials.gov